Cell therapy clinical trials 2012 – trends

by Alexey Bersenev on January 15, 2013 · 4 comments

in annual reports

As I proposed in 2011 report, cell trials tracking allows to identify some trends. Today I’d like to show you some interesting trends from 2011 to 2012.

First of all, I’d like to announce that 2011 report was updated! I’ve found a few more (6) trials, that I’ve missed, when finalized the report. My key words, by some reasons didn’t capture those trials.

Total number of trials
Total number of cell therapy trials, registered in databases increased from 2011 to 2012. I think it’s not a big jump, but good increase. This is positive and somewhat expected trend. First, the interest to the field is progressively increasing. Second, trialists were encouraged or obligated (US mandate to register trials in NCT database) to register trials in databases.


The number of cell therapy trials have increased in 2012, because the value of academic trials have increased. The number of industry-sponsored trials remained flat – from 50 in 2011 to 51 in 2012. I find this trend quite interesting.


US and China continue to dominate all other countries in number of cell therapy trials. Interestingly, the value of US and China out of top 10 countries remained flat for the last 2 years – about 31% of all trials in US and about 23% of all trials in China. From other “top 10 countries” – Iran, Spain and South Korea went up, India and Japan went down. UK didn’t make it in “top 10” and Nethderlads was a “newcomer” in 2012.

This graph represents a value of each country out total “top 10”:

If we look at regions in general, were no big moves from 2011 to 2012. Only South America went up from 1% in 2011 to 3% in 2012.


Cell types
The number of cell therapy trials increased in 2012 through the value of mesenchymal stromal cells (MSC), T-cells, bone marrow mononuclear cells (BM MNC), adipose tissue-derived MSC + stromal vascular fraction (SVF) and hematopoietic stem/ progenitor cells (HSPC). I’d especially emphasize a “big movers” – MSC and T-cells. Unlike T-cells, the other type of cellular immunotherapies – dendritic cells (DC) went down in 2012. Embryonic stem cells (ESC) remained pretty much flat (from 3 in 2011 to 2 in 2011).

This graph represents the total number of trials, involved some particular cell types (i picked the most interesting):

The value “stem” versus “non-stem” trials did not change and remained around 50/50 from 2011 to 2012. The same trend (flat) was observed for donor type – autologous from 63% in 2011 to 60% in 2012 and allogeneic from 37% in 2011 to 34% in 2012.

Cell type demographics
This is very interesting part of analysis. It turns out that some countries “like” some particular types of cells. T-cells is absolute US favorite. Almost all trials, involved umbilical cord-derived MSC, are going on in China! Adipose tissue-derived cells is the “most popular” cell type in Spain, followed by S. Korea and Japan.

The number of trials for cancer “skyrocketed” in 2012. Neurological conditions and eye diseases are remained flat. Number of trials for cardiovascular conditions, skin diseases, muskuloskeletal diseases and diabetes went up. The number of trials for liver diseases went down.


It was a snapshot of dataset analysis for 2011 and 2012. I was trying to pick the most interesting trends. As you can see, the data could be “sliced and diced” in many different ways. Please leave your comments and discuss these trends. Please let me know, what kind of trends you would be interested in.

How to cite:
Bersenev Alexey. Cell therapy clinical trials 2012 – trends. CellTrials blog. January 15, 2013. Available: http://celltrials.info/2013/01/15/cell-trials-2012-trends/

Follow real time updates via @CellTrials
Subscribe to this blog!

{ 4 comments… read them below or add one }

prasanna January 23, 2013 at 4:57 am

Dear Sir,
I wanted to know which are the companies and academic institutions are conducting cell therapy based clinical trials around the world or at least in Europe, China, Korea, Japan and ASEAN countries.


Alexey Bersenev January 29, 2013 at 8:17 pm

Please contact me directly on this matter.


ARGENTIN DIDIER January 29, 2013 at 11:05 am

Hello again Alexey,
Excellent complement to the 2012 report !
Your analysis confirms my understanding of the market, which is that the number of ongoing clinical trials increases, but rather slowly, particularly for the industry-sponsored trials ( see also the 2012 ARM report which mentions a 22% increase for the 2007-2012 period) ; regarding the academic trials, they might increase faster but your 2012 figures are somewow biased by the obligation/pressure to registrate the clinical trials, as well as additional databases/key words this year.
By the way, I cannot find the excell file similar to the 2011 one, gathering all the 226 trials, could you give me the link ?
Best regards,


Alexey Bersenev January 31, 2013 at 4:12 pm

Hi Didier,
Are academic institutions obligated to register trials but industry are not? In what countries? I’m not sure if this statement is correct. I’ll appreciate any proof links. It could be biased if academics “must register” in certain countries, but it how it is. I can not do anything about it. What I would like to know is that if anybody can confirm/ reject the bias – point trials (let’s say 10 of them), which were not registered, but launched somewhere. Do you have any data?

I re-searched 2011 by new key words and by exact names of companies, that’s why I added 6 more trials in updated version of 2011. If you can point more trials that I’ve missed, I’d be happy to update.

I don’t share raw data on public domain for 2012 and, probably will not do so in the future. The reason is that a great interest to these data from different organizations. I got few offers to collaborate.


Leave a Comment

Previous post:

Next post: